Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 30-35.doi: 10.6040/j.issn.1671-7554.0.2018.1423
WANG Haitao
CLC Number:
| [1] Committee on a framework for developing a new taxonomy of disease, Board on Life Sciences, Division on Earth and Life Studies, et al. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease[M]. Washington, DC: National Academies Press, 2011. [2] Siegel R, Ma JM, Zou ZH, et al. Cancer statistics, 2014[J]. CA A Cancer J Clin, 2014, 64(1): 9-29. [3] Logothetis CJ, Gallick GE, Maity SN, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer[J]. Cancer Discov, 2013, 3(8): 849-861. [4] Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance[J]. Cancer Res, 2008, 68(13): 5469-5477. [5] Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor[J]. Cancer Cell, 2010, 17(6): 535-546. [6] Magee JA, Chang LW, Stormo GD, et al. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element[J]. Endocrinology, 2006, 147(1): 590-598. [7] Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling[J]. Oncogene, 2001, 20(46): 6718-6723. [8] 孙李斌. FKBP51调控去势抵抗性前列腺癌形成的分子信号及机制研究[D]. 天津: 天津医科大学, 2016, [9] Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets[J]. Cancer Discov, 2011, 1(6): 487-495. [10] Kumar A, Rajendran V, Sethumadhavan R, et al. AKT kinase pathway: a leading target in cancer research[J]. Scientific World Journal, 2013, 2013: 756134. doi:10.1155/2013/756134. [11] Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate[J]. Nat Genet, 2009, 41(5): 619-624. [12] Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer[J]. Cell, 2015, 162(2): 454. doi:10.1016/j.cell.2015.06.053. [13] Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer[J]. N Engl J Med, 2016, 375(5): 443-453. [14] Goh CL, Eeles RA. Germline genetic variants associated with prostate cancer and potential relevance to clinical practice[J]. Recent Results Cancer Res, 2014, 202: 9-26. doi:10.1007/978-3-642-45195-9_2. [15] Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer[J]. J Clin Oncol, 2013, 31(14): 1748-1757. [16] Boysen G, Barbieri CE, Prandi D, et al. SPOP mutation leads to genomic instability in prostate cancer[J]. Elife, 2015, 4e09207. doi:10.7554/eLife.09207. [17] Ali M, Chung J, Dewal N, et al. 794PDProspective comprehensive genomic profiling(CGP)of 3, 343 primary and metastatic site prostate tumors[J]. Annals of Oncology, 2018, 29(suppl_8): doi:10.1093/annonc/mdy284.003. [18] Spratt DE, Zumsteg ZS, Feng FY, et al. Translational and clinical implications of the genetic landscape of prostate cancer[J]. Nat Rev Clin Oncol, 2016, 13(10): 597-610. [19] Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer[J]. Cell, 2015, 163(4): 1011-1025. [20] 中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. 中国前列腺癌患者基因检测专家共识(2018年版)[J]. 中国癌症杂志, 2018, 28(8): 627-633. Prostate Cancer Working Group of China Anti-Cancer Association Genitourinary Cancer Committee. Expert consensus on genetic testing in Chinese prostate cancer patients(2018 edition)[J]. China Oncology, 2018, 28(8): 627-633. [21] Antonarakis ES, Lu CX, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer[J]. N Engl J Med, 2014, 371(11): 1028-1038. [22] Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer(NEPC)progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis[J]. J Clin Oncol, 2014, 32(30): 3383-3390. [23] Maira SM, Pecchi S, Huang AL, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor[J]. Mol Cancer Ther, 2012, 11(2): 317-328. [24] Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer[J]. Cancer Cell, 2011, 19(5): 575-586. [25] Mateo J, Sandhu S, Miranda S, et al. Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer[J]. Cancer Res, 2015, 75(15 Supplement): CT322. doi: 10.1158/1538-7445. am2015-ct322. [26] Sunkel B, Wu DY, Chen Z, et al. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence[J]. Nucleic Acids Res, 2017, 45(11): 6993. doi:10.1093/nar/gkx282. [27] de Bono JS, Hussain M, Thiery-Vuillemin A, et al. PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration[J]. JCO, 2017, 35(15_suppl): TPS5091. doi:10.1200/jco.2017.35.15_suppl.tps5091. [28] Cheng HH, Pritchard CC, Boyd T, et al. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer[J]. Eur Urol, 2016, 69(6): 992-995. [29] Rae C, Mairs RJ. Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells[J]. International journal of radiation biology, 2017, 93(2): 194-203. [30] Petersen C, Mansour WY, Koetter A, et al. PO-0745: Switch to PARP1-dependent endjoining: Olaparib-mediated radiosensitization in prostate cancer cells[J]. Radiotherapy and Oncology, 2015, 115: S369. doi:10.1016/S0167-8140(15)40737-6. [31] Li J, Wang RX, Kong YF, et al. Targeting plk1 to enhance efficacy of olaparib in castration-resistant prostate cancer[J]. Mol Cancer Ther, 2017, 16(3): 469-479. [32] Zhang W, Liu B, Wu W, et al. Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer[J]. Clinical Cancer Research, 2018, 24(3): 696-707. [32] Zhang W, Liu B, Wu WH, et al. Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer[J]. Clin Cancer Res, 2018, 24(3): 696-707. [33] Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 975-986. [34] Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(7): 700-712. [35] Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer[J]. Oncotarget, 2016, 7(33): 52810-52817. [36] Pai-Scherf L, Blumenthal GM, Li H, et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond[J]. Oncologist, 2017, 21(11):1392-1399. [37] Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer[J]. Cell, 2018, 173(7): 1770-1782. [38] Karzai F, Madan RA, Owens H, et al. A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer(mCRPC)in an unselected population[J]. JCO, 2018, 36(6_suppl): 163. doi:10.1200/jco.2018.36.6_suppl.163. [39] Wang HT, Zhang J, Wei SQ. Histological and molecular phenotype changes of castration-resistant prostate cancer and acquired resistance to hormonal therapy[C]. Chiago: ASCO, 2015, e16006. |
| [1] | Linlin WANG,Yuping SUN. From the perspective of clinicians: the application and reflection of artificial intelligence in cancer precision diagnosis and treatment [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 89-96. |
| [2] | Jun YANG. Medico-engineering cooperation: a strategic plateau of neurosurgery innovation and development in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 83-88. |
| [3] | Chuanxin WANG. Liquid biopsy of tumor [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 64-71. |
| [4] | SONG Lijin, GU Xiang, LI Lixiang, LI Ming, ZUO Xiuli, LI Yanqing. Effects of Fusobacterium nucleatum gavage on the intestinal microbiota of rats [J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 7-14. |
| [5] | WANG Hongyang. Development of tumor biomarkers in the age of precision medicine [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 1-2. |
| [6] | ZHAO Li, LI Lixiang, CHEN Feixue, ZUO Xiuli, LI Yanqing. Effect of Bacillus subtilis gavage on the intestinal microbiota of mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 28-35. |
| [7] | GAO Rui1, GAN Shang-quan2. Analysis of small RNAs induced by cerebral ischemia reperfusion injury [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(10): 83-. |
|
||
